Rx Coupon Stakeholders Seek Clarity On Use In Exchanges
This article was originally published in The Pink Sheet Daily
Letters from patient advocacy organizations express confusion over recent government statements on the use of patient assistance programs in the state insurance marketplaces. Drug manufacturers are also anxious for more definitive guidance.
You may also be interested in...
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.